BIONOMICS LIMITED (BNO)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
BNO - BIONOMICS LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -1.44
Index:
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.023
23 Mar |
0.000 OPEN $0.02 |
0.000 HIGH $0.02 |
1,143,048 LOW $0.02 |
| OTHER COMPANIES IN THE SAME SECTOR | |||
| CUV . ACR . AHZ . CSL . IDT . IVX . MSB . MYX . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . OCC . ACW . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . HXL . MXC . MAP . CAU . OPT . ANP . TRP . BIO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -1.6 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 0.3 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 4.2 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -21.7 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -8,253.62 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -41.64 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -41.16 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -36.39 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -41.64 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -51.16 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -21.7 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 13 M |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 34 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 1.19 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.0 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 0.59 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 1 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 26 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 16 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
BNO STOCK CHART
FNArena News on BNO
| 1 |
Australian Broker Call *Extra* Edition – Sep 27, 2019Sep 27 2019 - Daily Market Reports |
| 2 |
Rudi’s View: CSL, ResMed, And Ramsay Health CareJul 05 2018 - Rudi's View |
| 3 |
Two Threats To ConquerJul 12 2017 - Rudi's View |
| 4 |
Weekly Broker Wrap: FY15 Preview, TV, Fund Managers, Retail And CancerJul 24 2015 - Weekly Reports |
| 5 |
The Short ReportJul 03 2014 - Australia |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Telix Pharmaceuticals’ Pipeline Full Of PromiseMar 21 2023 - Small Caps |
| 2 |
FDA Approval Puts Rocket Under Neuren SharesMar 16 2023 - Small Caps |
| 3 |
Dr Boreham’s Crucible: Actinogen MedicalNov 30 2022 - Small Caps |
| 4 |
Dr Boreham’s Crucible: Qbiotics GroupNov 09 2022 - Small Caps |
| 5 |
Dr Boreham’s Crucible: PharmaxisOct 05 2022 - Small Caps |
| 6 |
Brokers Review Prospects For CSLSep 30 2022 - Australia |
| 7 |
Dr Boreham’s Crucible: Inoviq LtdSep 19 2022 - Small Caps |
| 8 |
CSL: Offering Buying OpportunitySep 13 2022 - Technicals |
| 9 |
Dr Boreham’s Crucible: Vaxxas Pty LtdSep 07 2022 - FYI |
| 10 |
Dr Boreham’s Crucible: Telix PharmaceuticalsAug 22 2022 - Small Caps |
